EPIOMED THERAPEUTICS

Epiomed Therapeutics is focused on the discovery and development of novel anti-emetic compounds for both the human and veterinary markets.

Epiomed Therapeutics, Inc. (a Delaware Corporation) was formed in late 2010 based upon technology discovered at Cenomed BioSciences, LLC and assigned to the Epiomed by Cenomed, Inc. The vision of the co-founders (David Helton, Ernest Pfadenhauer and Richard Burgoon) was to establish a drug discovery and development organization with a specific therapeutic focus, i.e., emesis, and target the intellectual, scientific, human and financial resources of the Company on that focus. This vision further included the objective of going back to the early days of the biopharmaceutical industry targeting the vast majority of the Company financial resources on drug discovery and development, working virtually with limited infrastructure.